Valuation: Kamada Ltd.

Market Cap 1.25B 0 409M 359M 334M 307M 576M 39.4B 585M 3.97B 1.55B 19.37B 1.54B 1.5B 66.97B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.25B 0 409M 359M 334M 307M 576M 39.4B 585M 3.97B 1.55B 19.37B 1.54B 1.5B 66.97B EV / Sales 2026 *
2.08x
EV / Sales 2027 * 1.9x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 2015-06-30
Director of Finance/CFO 55 2017-12-30
Chief Operating Officer 53 2016-10-31
Director TitleAgeSince
Director/Board Member 75 1990-12-12
Chairman 77 2013-03-06
Chairman 55 2020-08-11
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-1.04% - - 409M
+0.63%-3.06%+16.50%-10.12% 66.74B
+1.23%+2.80%+38.09%+200.66% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
-1.32%-7.38%-57.37%-56.96% 38.25B
+0.78%-1.84%+53.73%-25.20% 29.85B
+0.84%+0.36%+67.62%+84.46% 23.51B
-5.17%-12.54%+58.33%-55.63% 21.45B
-1.21%+1.12%+0.90%+164.17% 19.97B
+1.31%+3.24%+81.47%+157.97% 16.47B
Average +0.66%-0.53%+34.56%+56.79% 35.3B
Weighted average by Cap. +1.48%+0.11%+29.07%+51.17%

Financials

2026 *2027 *
Net sales 600M 0 197M 173M 161M 148M 278M 18.98B 282M 1.91B 747M 9.33B 740M 724M 32.26B 655M 0 215M 189M 176M 161M 303M 20.7B 307M 2.08B 814M 10.17B 807M 789M 35.18B
Net income 73.89M 0 24.26M 21.31M 19.82M 18.18M 34.17M 2.34B 34.69M 235M 91.93M 1.15B 91.08M 89.11M 3.97B 105M 0 34.62M 30.4M 28.27M 25.94M 48.75M 3.33B 49.5M 336M 131M 1.64B 130M 127M 5.67B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-